Every 8-K that Arrowhead Research Corporation (ARWR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ARWR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARWR filings page.
Arrowhead Pharmaceuticals reported fiscal 2026 third quarter results for the period ended June 30, 2026. Revenue was $75,253 thousand, up from $27,767 thousand a year earlier, while total operating expenses rose to $245,346 thousand, leading to a net loss attributable to Arrowhead of $194,280 thousand, or $(1.36) per diluted share.
Total cash resources, including cash and available-for-sale securities, were $1,566,886 thousand at June 30, 2026, against total liabilities of $1,645,972 thousand, including $682,707 thousand of convertible notes. REDEMPLO® commercial momentum continued, with prescription volume roughly doubling and new marketing authorizations in the EU and Australia.
Topline Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran in severe hypertriglyceridemia showed median triglyceride reductions of 79% and 81%, and a 78% reduction in acute pancreatitis events, including 100% reduction in a highest‑risk subgroup. Arrowhead acquired an FDA priority review voucher and signed a global license for ARO‑PNPLA3 with Madrigal, receiving a $25 million upfront payment and eligibility for up to $975 million in milestones.
Arrowhead Pharmaceuticals, Inc. announced that its Board of Directors appointed Dr. Matt Cohen, M.D., M.B.A., as a director, effective June 12, 2026. Dr. Cohen brings more than 25 years of healthcare investing and portfolio management experience, including senior roles at JP Morgan Asset Management and Vida Ventures.
He will receive standard non-employee director compensation plus a sign-on grant of restricted stock units valued at $887,000, scheduled to vest over three years. The company states there are no family relationships or appointment-related arrangements with other persons, and Dr. Cohen will enter into Arrowhead’s standard indemnity agreement.
Arrowhead Pharmaceuticals reported fiscal 2026 second quarter revenue of $73.7 million, down sharply from $542.7 million a year earlier, leading to a net loss of $132.7 million or -$0.93 per diluted share versus net income of $370.4 million or $2.75 previously. Total cash resources rose to $1.78 billion as of March 31, 2026, supported by concurrent offerings of $700 million in 0.00% convertible senior notes due 2032 and a $230 million common equity issuance, plus a capped call to limit dilution.
The company highlighted growing commercial traction for REDEMPLO in familial chylomicronemia syndrome, with more than 400 prescriptions, about 180 patients shipped, and most use in patients new to the APOC3 class. Arrowhead also expanded REDEMPLO’s global regulatory footprint, advanced its RNAi pipeline in cardiometabolic disease and obesity, and signed a worldwide license with Madrigal Pharmaceuticals for ARO-PNPLA3, including a $25 million upfront payment and up to $975 million in potential milestones.
Arrowhead Pharmaceuticals reported results of its 2026 annual stockholder meeting. Stockholders elected seven directors to the board, with vote totals for each nominee ranging from about 70.4 million to 100.8 million votes in favor.
Stockholders rejected the advisory Say-on-Pay proposal, with 41,625,740 votes for and 59,963,903 votes against, signaling dissatisfaction with executive compensation. They approved the Amended and Restated 2021 Incentive Plan and ratified KPMG LLP as independent auditors. As of the January 22, 2026 record date, 140,010,690 common shares were outstanding and entitled to vote.
Arrowhead Pharmaceuticals, Inc. filed a current report to note that it has announced and discussed its fiscal 2026 financial results for the period ended December 31, 2025. These results were shared through a press release dated February 5, 2026.
The press release is provided as Exhibit 99.1 and is designated as “furnished” rather than “filed,” which limits its use in certain legal contexts. The company also included an Inline XBRL cover page data file as Exhibit 104, signed on behalf of Arrowhead by Chief Financial Officer Daniel Apel.
Arrowhead Pharmaceuticals issued $700,000,000 of 0.00% Convertible Senior Notes due 2032. These unsecured senior notes carry no regular interest and mature on January 15, 2032, with noteholders able to convert earlier under specified conditions and freely from October 15, 2031 until shortly before maturity.
The initial conversion rate is 11.4844 shares per $1,000 principal amount, implying an initial conversion price of about $87.07 per share, subject to customary adjustments and potential increases after certain make‑whole events. Arrowhead may redeem the notes on or after January 16, 2029 if its share price exceeds 130% of the conversion price for defined trading periods, and holders can require repurchase after specified fundamental changes.
In connection with the offering, Arrowhead entered into capped call transactions that cover the shares underlying the notes. The capped calls cost approximately $47.9 million and have an initial cap price of about $119.33 per share, which is described as an 85.0% premium to the public offering price in a concurrent equity offering, aiming to limit dilution and/or offset cash paid above principal on conversion.
Arrowhead Pharmaceuticals is raising capital through an equity offering and a convertible notes sale. The company agreed to sell 3,100,776 shares of common stock at $64.50 per share and, for certain investors, pre-funded warrants to purchase up to 1,550,387 shares at $64.499 per warrant. Underwriters also exercised a 30-day option for an additional 456,116 shares.
The equity transactions are expected to generate net proceeds of approximately $216.6 million. Arrowhead is also issuing $625,000,000 of 0.00% convertible senior notes due 2032, plus an additional $75,000,000 option that underwriters exercised in full, with expected net proceeds of about $681.3 million. Both offerings are made under an automatic shelf registration statement and are expected to close in January 2026, subject to customary conditions.
Arrowhead Pharmaceuticals reported interim Phase 1/2a results for its RNAi obesity candidates ARO-INHBE and ARO-ALK7. A single 400 mg dose of ARO-INHBE in adults with obesity achieved a mean maximum reduction in serum Activin E of -85%, with a maximum observed reduction of -94%. As monotherapy, ARO-INHBE led by week 16 to a mean visceral fat reduction of -9.9%, a mean liver fat relative reduction of -38%, and an increase in total lean tissue of 3.6%, with two doses at week 24 achieving a -15.6% mean visceral fat reduction adjusted for placebo.
In obese patients with type 2 diabetes on tirzepatide, adding two 400 mg doses of ARO-INHBE roughly doubled weight loss at week 16 (-9.4% vs -4.8%) and produced larger fat reductions, including liver fat relative reduction of -76.7% vs -20%. ARO-INHBE was generally well tolerated, with mostly mild events and one serious limb abscess deemed unrelated. ARO-ALK7 showed adipocyte target silencing with mean adipose ALK7 mRNA reduction of -88% at 200 mg and a -14.1% placebo-adjusted visceral fat reduction at week 8, with a generally favorable safety profile and no serious adverse events.
Arrowhead Pharmaceuticals, Inc. reported that it has announced and commented on its fiscal 2025 financial results for the period ended September 30, 2025. The announcement was made on November 25, 2025.
The company provided these results in a press release that is included as Exhibit 99.1, with an additional Exhibit 104 covering the interactive data for the cover page. The report was signed on behalf of the company by Chief Financial Officer Daniel Apel.
Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare lipid disorder. This marks a significant regulatory milestone for the company, adding an FDA‑approved therapy to its portfolio. Arrowhead also held a conference call to discuss the approval and provided a detailed press release and slide presentation as exhibits to the report.
Arrowhead Research Corporation (ARWR) filed an 8-K reporting a material event that primarily contains forward-looking statement disclosures and a brief litigation update. The company states it intends to vigorously pursue its claims in an ongoing lawsuit and refers to planned commercialization efforts for its investigational drug plozasiran. The filing cites uncertainties tied to the Ionis letter, the validity and enforceability of the '333 Patent, the company’s broader patent portfolio, and the outcome of the lawsuit. It emphasizes that forward-looking statements are based on current expectations and that actual results may differ materially due to risks described in prior SEC filings.
Arrowhead Research entered an exclusive licensing agreement with Novartis for ARO-SNCA, a preclinical RNAi therapeutic targeting Parkinson's disease and other synucleinopathies. Arrowhead will complete preclinical work while Novartis is responsible for clinical development, manufacturing, and commercialization. Arrowhead will receive a $200 million upfront payment, potential up to $2 billion in development, regulatory, and sales milestones, and is eligible for tiered royalties up to the low double digits on net product sales. The transactions are subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino waiting period. The full agreement text will be filed as an exhibit to Arrowhead's annual report for the year ending September 30, 2025.